Wenying Zhang

ORCID: 0000-0002-0880-4447
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Advancements in Solid Oxide Fuel Cells
  • Lymphoma Diagnosis and Treatment
  • Electronic and Structural Properties of Oxides
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • Crystallography and molecular interactions
  • Luminescence and Fluorescent Materials
  • Nanoplatforms for cancer theranostics
  • Immunotherapy and Immune Responses
  • Electrocatalysts for Energy Conversion
  • Magnetic and transport properties of perovskites and related materials
  • Structural Load-Bearing Analysis
  • Metal complexes synthesis and properties
  • Magnetism in coordination complexes
  • Structural Behavior of Reinforced Concrete
  • Nonlinear Optical Materials Studies
  • Virus-based gene therapy research
  • Metal-Organic Frameworks: Synthesis and Applications
  • Advanced materials and composites
  • Neutropenia and Cancer Infections
  • Molecular Sensors and Ion Detection
  • Cytokine Signaling Pathways and Interactions

Sichuan University of Science and Engineering
2025

Changchun Institute of Applied Chemistry
2023-2025

Chinese Academy of Sciences
2023-2025

State Key Laboratory of Rare Earth Resources Utilization
2025

Zhengzhou University
2015-2024

China University of Geosciences
2014-2024

Tianjin University of Traditional Chinese Medicine
2024

Beijing University of Technology
2024

Humboldt-Universität zu Berlin
2024

Charité - Universitätsmedizin Berlin
2024

Abstract Purpose: Relapsed or refractory Hodgkin lymphoma is a challenge for medical oncologists because of poor overall survival. We aimed to assess the feasibility, safety, and efficacy CD30-targeting CAR T cells in patients with progressive relapsed lymphoma. Experimental Design: Patients received conditioning chemotherapy followed by CART-30 cell infusion. The level transgenes peripheral blood biopsied tumor tissues was measured periodically according an assigned protocol quantitative...

10.1158/1078-0432.ccr-16-1365 article EN Clinical Cancer Research 2016-09-01

Abstract Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, high rate of responses is sometimes limited emergence CD19-negative leukemia. Bispecific CAR-modified T cells targeting both and CD22 may overcome limitation relapse. Methods We here report design a bispecific CAR simultaneous CD22. performed phase 1 trial patients with relapsed/refractory precursor B-ALL at dose that ranged from 1.7 × 10 6 to 3 per kilogram body weight. Results...

10.1186/s13045-020-00856-8 article EN cc-by Journal of Hematology & Oncology 2020-04-03

The enhancement of two-photon absorption cross-section, fluorescence quantum yield and singlet oxygen generation efficiency for organic dyes their applications in excited imaging photodynamic therapy are summarized.

10.1039/d0tc00563k article EN Journal of Materials Chemistry C 2020-01-01

Adoptive immunotherapy with T cells expressing a tumor-associated chimeric antigen receptor (CAR) provides promising approach for tumor therapy. We designed clinical trial multiple myeloma (MM) treatment CAR-modified recognizing CD138 (CART-138). Five patients diagnosed chemotherapy-refractory MM were enrolled into this trial, although one later advanced to plasma cell leukemia. By intravenous infusions, these received CD3+ CART-138 in an escalating dose. No intolerable toxicity was observed...

10.1016/j.jocit.2014.11.001 article EN cc-by-nc-nd Journal of Cellular Immunotherapy 2015-02-18

The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims establish cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial autologous or donor- derived cells genetically modified CAR targeting the B-cell CD19 harboring 4-1BB and CD3ζ moiety. All enrolled patients had relapsed chemotherapy-refractory lineage acute lymphocytic leukemia (B-ALL). Of nine patients, six definite extramedullary involvement, rate overall survival at 18 weeks...

10.1080/2162402x.2015.1027469 article EN OncoImmunology 2015-05-26

Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis. Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were effective in phase I clinical trial for patients advanced B-cell lymphomas. We performed IIa to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) CD20+ lymphoma. Eleven enrolled, seven underwent cytoreductive chemotherapy debulk tumors deplete lymphocytes before receiving T-cell...

10.1038/sigtrans.2016.2 article EN cc-by Signal Transduction and Targeted Therapy 2016-03-11

Owing to the often-similar physical and chemical properties of structural isomers organic molecules, large efforts have been made develop efficient strategies isolate specific isomers. However, facile separation regioisomeric compounds remains difficult. Here we demonstrate a universal organometallic capsule in which two silver centers are rigidly separated from each other by tetranuclear [Rh4] pyramidal frustums, selectively encapsulate isomer mixtures. Not only is present heterometallic...

10.1021/jacs.6b06622 article EN Journal of the American Chemical Society 2016-07-27

Background: The negative signaling provided by interactions of the co-inhibitory molecule, programmed death-1 (PD-1), and its ligands, B7-H1 (PD-L1) B7-DC (PD-L2), is a critical mechanism contributing to tumor evasion; blockade this pathway has been proven enhance cytotoxic activity mediate antitumor therapy. Here we evaluated anti-tumor efficacy AAV-mediated delivery extracellular domain murine PD-1 (sPD-1) site. Material Methods: An rAAV vector was constructed in which expression sPD-1,...

10.7314/apjcp.2012.13.8.4031 article EN cc-by Asian Pacific Journal of Cancer Prevention 2012-08-31

Pyroptosis hold great potential in tumor therapy due to its strong immunogenicity. Several strategies, including ion interference (IIT), are developed induce pyroptosis. However, the mechanism by which metal oxoanions induced pyroptosis remained unclear. It was reported that MoO42− ions could stimulate immune responses, but their pyroptosis‐inducing mechanisms were not fully understood. Herein, we synthesized uniform and dispersed silver molybdate (Ag2MoO4) nanoparticles (AMO) via a...

10.1002/ange.202501530 article EN Angewandte Chemie 2025-02-17

Pyroptosis hold great potential in tumor therapy due to its strong immunogenicity. Several strategies, including ion interference (IIT), are developed induce pyroptosis. However, the mechanism by which metal oxoanions induced pyroptosis remained unclear. It was reported that MoO42− ions could stimulate immune responses, but their pyroptosis‐inducing mechanisms were not fully understood. Herein, we synthesized uniform and dispersed silver molybdate (Ag2MoO4) nanoparticles (AMO) via a...

10.1002/anie.202501530 article EN Angewandte Chemie International Edition 2025-02-17

Amidst the increasingly severe global environmental crisis, application of artificial intelligence (AI) in fields governance and sustainable development has become a hot topic current scientific research practice. The complexity urgency issues have made integration AI technology particularly important pressing. To comprehensively understand status, hotspots, future trends this field, study employed Citespace VOSviewer literature analysis tools to construct knowledge map based on data from...

10.63333/eem.v1n13 article EN cc-by 2025-03-06
Coming Soon ...